Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124301 | 0.77 | TSHR (0.31) | TSHRTDP1 | |
| SCHEMBL2749956 | 0.77 | TSHR (0.31) | TSHRTDP1 | |
| SCHEMBL124302 | 0.77 | TSHR (0.31) | TSHRTDP1 | |
| SCHEMBL5689546 | 0.72 | — | — | |
| SCHEMBL6832062 | 0.72 | — | — | |
| SCHEMBL10486705 | 0.72 | — | — | |
| SCHEMBL984815 | 0.69 | — | — | |
| SCHEMBL5678359 | 0.69 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL506587 | 0.69 | — | — | |
| SCHEMBL255617 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178077-B2 | Drug development target protein and target gene, and method of screening | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8153385-B2 | Target protein and target gene in drug designing and screening method | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100136524-A1 | TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20090233274-A1 | DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING | REVERSE PROTEOMICS RESEARCH INSTITUTE CO. (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233274-A1 | DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING | NCS1, PRSS12, TPX2 | TSHR 3460/4885TDP1 2541/4885 |
| US-20100136524-A1 | TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD | CHP1, CMA1, CARHSP1 | TSHR 4022/4885TDP1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.